Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trial

References

• Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Neurology41M, 617–618 (1991).
   Google Scholar
• Chiò A, Cocito D, Bottacchi E, Buffa et al. Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J. Neurol. Neurosurg. Psychiatry78, 1349–1353 (2007).
   PubMed Web of Science ®Google Scholar
• Joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. J. Peripher. Nerv. Syst.10, 220–228 (2005).
   PubMed Web of Science ®Google Scholar
• Köller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. N. Engl. J. Med.352, 1343–1356 (2005).
   PubMed Web of Science ®Google Scholar
• Salomon B, Rhee L, Bour-Jordan H et al. Development of spontaneous autoimmune peripheral polyneuropathy in B7–2-deficient NOD mice. J. Exp. Med.194, 677–684 (2001).
   PubMedGoogle Scholar
• Hughes RA, Allen D, Makowska A, Gregson NA. Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. J. Peripher. Nerv. Syst.11, 30–46 (2006).
   PubMed Web of Science ®Google Scholar
• Yan WX, Archelos JJ, Hartung HP, Pollard JD. P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Neurol.50, 286–292 (2001).
   PubMed Web of Science ®Google Scholar
• Sanvito L, Makowska A, Mahdi-Rogers M et al. Humoral and cellular immune responses to myelin protein peptides in chronic inflammatory demyelinating polyradiculoneuropathy. J. Neurol. Neurosurg. Psychiatry80(3), 333–338 (2009).
   PubMed Web of Science ®Google Scholar
• Hughes RA, Swan AV, van Doorn PA. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev.4, CD003280 (2004).
   Google Scholar
• Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA291, 2367–2375 (2004).
   PubMed Web of Science ®Google Scholar
• Enders U, Toyka KV, Hartung HP, Gold R. Failure of intravenous immunoglobulin (IVIg) therapy in experimental autoimmune neuritis (EAN) of the Lewis rat. J. Neuroimmunol.76, 112–116 (1997).
   PubMed Web of Science ®Google Scholar
• Gabriel CM, Gregson NA, Redford EJ, Davies M, Smith K, Hughes RAC. Human immunoglobulin ameliorates rat experimental autoimmune neuritis (EAN). Brain120, 1533–1540 (1997).
   PubMed Web of Science ®Google Scholar
• Lin HH, Spies JM, Lu JL, Pollard JD. Effective treatment of experimental autoimmune neuritis with human immunoglobulin. J. Neurol. Sci.256, 61–67 (2007).
   PubMedGoogle Scholar
• Vermeulen M, van Doorn PA, Brand A, Strengers PF, Jennekens FG, Busch HF. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J. Neurol. Neurosurg. Psychiatry56, 36–39 (1993).
   PubMed Web of Science ®Google Scholar
• Hahn AF, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind placebo-controlled crossover study. Ann. Neurol.32, 294–295 (1992).
   Google Scholar
• Mendell JR, Barohn RJ, Freimer ML et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology56, 445–449 (2001).
   PubMed Web of Science ®Google Scholar
• Thompson N, Choudhary P, Hughes RA, Quinlivan RM. A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. J. Neurol.243, 280–285 (1996).
   PubMed Web of Science ®Google Scholar
• van Schaik I, Winer JB, De Haan R, Vermeulen M. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev.2, CD001797 (2002).
   Google Scholar
• Hughes RA, Donofrio P, Bril V et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol.7, 136–144 (2008).
   PubMed Web of Science ®Google Scholar
• Hughes RAC, Bensa S, Willison HJ et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Neurol.50, 195–201 (2001).
   PubMed Web of Science ®Google Scholar
• Bril V, Katzberg H, Donofrio P et al. Electrophysiology in CIDP: results of a clinical treatment trial with IGIV. Muscle Nerve39(4), 448–455 (2009).
   PubMedGoogle Scholar
• Merkies ISJ, Bril V, Dalakas MC et al. Health-related quality-of-life improvements in CIDP with immune globulin IV 10%: The ICE Study. Neurology72(15), 1337–1344 (2009).
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Clark WM. Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record. Neurology60, 1736–1737 (2003).
   PubMedGoogle Scholar
• McCrone P, Chisholm D, Knapp M et al. Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. Eur. J. Neurol.10, 687–694 (2003).
   PubMed Web of Science ®Google Scholar
• Koller H, Schroeter M, Feischen H, Hartung HP, Kieseier BC. Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies. J. Neurol.253, 1505–1506 (2006).
   PubMed Web of Science ®Google Scholar
• Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat. Biotechnol.25, 1256–1264 (2007).
   PubMed Web of Science ®Google Scholar
• RMC Trial Group. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol.8, 158–164 (2009).
   PubMed Web of Science ®Google Scholar
• Hirst C, Raasch S, Llewelyn G, Robertson N. Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H). J. Neurol. Neurosurg. Psychiatry77, 800–802 (2006).
   PubMed Web of Science ®Google Scholar